Saying no isn't NICE - The travails of Britain's National Institute for Health and Clinical Excellence

New England Journal of Medicine

Volumn 359, Issue 19, 2008, Pages 1977-1981

  Steinbrook, Robert ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BEVACIZUMAB; CAPECITABINE; LAPATINIB; PEGAPTANIB; RANIBIZUMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

BREAST CANCER; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG COST; DRUG EFFICACY; DRUG MARKETING; FRAGILITY FRACTURE; HEALTH CARE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HEALTH SERVICE; HUMAN; KIDNEY CANCER; MEDICAL SOCIETY; MEDICAL TECHNOLOGY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RETINA MACULA DEGENERATION; SHORT SURVEY;

EID: 57349096844     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp0806862     Document Type: Article

References (5)

1. Rawlins MD. NICE work - providing guidance to the British National Health Service. N Engl J Med 2004;351:1383-5.
2. House of Commons Health Committee. First report of session 2007-8. London: Stationery Office, January 10, 2008. (Accessed October 17, 2008, at http://www.publications.parliament.uk/pa/cm200708/cmselect/cmhealth/27/27.pdf.)
3. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. June 2008. (Accessed October 17, 2008, at http://www.nice.org.uk/aboutnice/howwework/devnicetech/ technologyappraisalprocessguides/guidetothemethodsoftechnologyappraisal.jsp.)
4. American College of Physicians. Information on cost-effectiveness: an essential product of a national comparative effectiveness program. Ann Intern Med 2008;148:956-61.
5. Grosse SD. Assessing cost-effectiveness in healthcare: the history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 2008;8:165-78.